Management Team & Board of Directors

Mr. Capper joined MIMEDX in January 2023 to lead the Company as Chief Executive Officer and Director. A highly experienced and accomplished healthcare executive, he brings nearly 30 years of experience in MedTech and Life Sciences leadership roles along with a track record of substantial value creation.

Mr. Capper has successfully led several organizations, most recently serving as the CEO of BioTelemetry, guiding the company through a significant turn-around, which culminated with its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he served as President and CEO of both Home Diagnostics and CCS Medical. Mr. Capper brings with him a wealth of commercial experience, having held several leadership roles earlier in his career during the decade he spent with Bayer AG. Additionally, he was an officer in the U.S. Navy serving with distinction as a naval aviator.

Mr. Capper received his undergraduate degree in Accounting from West Chester University and MBA in
International Finance from George Washington University.

Mr. Rice joined MIMEDX in July 2023 as the Company’s Chief Financial Officer. He brings more than a decade of experience in the MedTech industry having served in several executive leadership positions throughout his career. Most recently, he served as the CFO of Orthofix Medical, a leading global spine and orthopedics company. Prior to Orthofix, Mr. Rice was CFO at Vision Source, held several finance leadership roles at both McAfee and Concentra, and started his career at PricewaterhouseCoopers.  

Mr. Rice is a Certified Public Accountant and received his BBA with honors and his MBA from Southern Methodist University.

Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company’s negative pressure wound care technology. During his tenure at KCI, Dr. Harper also led the company’s Clinical Development and Regulatory Affairs organization.  Prior to KCI, he served as Vice President of Clinical Development and Clinical Sciences at the biotechnology company LifeCell Corporation, the previous Regenerative Medicine division of Acelity and the leader in acellular scaffold technology and makers of AlloDerm, Strattice, and GraftJacket Regenerative and Reconstructive Tissue Matrices.

Dr. Harper has over 40 peer-reviewed publications and book chapters and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing.  He currently serves as a member of the Board of Directors at Kent Imaging, Nanomedic Technologies, and American College of Wound Healing and Tissue Repair.

He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, California and the National Cancer Institute in Bethesda, Maryland.

Mr. Hulse joined MIMEDX in December 2019, and brings to MIMEDX more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.

Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.

Ms. Moller joined MIMEDX in August 2020 as Senior Vice President, Sales and was appointed Chief Commercial Officer in June 2024. She brings significant sales leadership experience, clinical knowledge and understanding of the Advanced Wound Care marketplace to her role. With more than 25 years of experience in sales roles with increasing responsibility, Ms. Moller has managed national sales teams and executed on strategic growth initiatives for leading healthcare companies, including 3M and its subsidiaries Acelity and KCI.

Ms. Moller holds a B.S. in Nursing (BSN) from University of Phoenix and an MBA from Colorado Christian University.

A proven HR executive, Ms. Surdez brings more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organizational change management for several successful IPOs and large multinational biotech companies.

She has held a variety of HR roles with increasing responsibility, most recently as the Head of HR for Vaxxinity, a clinical-stage biotech at which she built the HR function from the ground up. Prior thereto, she served as Senior Vice President of HR for Viela Bio, a successful biotech start-up spun out of AstraZeneca that was later acquired by Horizon Therapeutics. Earlier in her career, she provided HR support to multiple functions within the biologics and small molecule teams at MedImmune/AstraZeneca.

Ms. Surdez holds a B.A. in History from the University of North Carolina at Wilmington.

Ms. Whitlow joined MIMEDX in January 2023 as Chief Operating Officer. With a demonstrated background in operational leadership, Ms. Whitlow brings to her role more than 30 years of Life Sciences and Pharmaceutical experience.

She has held a variety of senior executive roles, most recently as President, Clinical Supply Services at Catalent Pharma Solutions. Prior to her role at Catalent, Ms. Whitlow’s extensive career has included leadership positions at a number of MedTech and Pharmaceutical companies, including Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.

Ms. Whitlow holds a B.S. in Industrial Engineering from Texas A&M University and an MBA from the NYU/LSE/HEC TRIUM program.

Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009 (Chairwoman of the Board since April 2015) and IGM Biosciences, Inc., a privately held biotechnology company, since January 2019.

Dr. Behrens has worked as an independent life sciences consultant and investor since December 2009. She served as the Co-Founder, President, Chief Executive Officer and as a director of the KEW Group Inc., a private oncology services company, from January 2012 until June 2014.

Earlier in her career, Dr. Behrens served as a general partner for selected venture funds for RS Investments, a mutual fund firm, from 1996 until December 2009. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a managing director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. During that time, Dr. Behrens also served as a member of the President’s Council of Advisors on Science and Technology (PCAST), from 2001 to 2009 and as chairwoman of PCAST’s Subcommittee on Personalized Medicine, as well as the President, director and chairwoman of the National Venture Capital Association, an organization that advocates for public policy that supports the American Entrepreneurial ecosystem, from 1993 until 2000. Prior to that, she served as a general partner and managing director for Robertson Stephens & Co., an investment company, from 1983 through 1996.

She served as a director of Amylin Pharmaceuticals, Inc. (formerly AMLN), a biopharmaceutical company, from 2009 until the company’s sale in 2012 to Bristol-Myers Squibb Co. Prior to that, she served on the board of directors Abgenix, Inc. (formerly ABGX), a biopharmaceutical company, from 2001 until the company was sold to Amgen, Inc. in 2006. From 1997 to 2005, Dr. Behrens was a director of the Board on Science, Technology and Economic Policy for the National Research Council.

Dr. Behrens was also a Co-Founder of the Coalition for 21st Century Medicine, a trade association for new generation diagnostics companies.

Dr. Behrens holds a B.S. in Biology and a Ph.D. in Microbiology from the University of California, Davis.

Mr. Newton joined MIMEDX’s Board in 2019, and has since served as Chair of the Audit Committee and as a member of the Ethics and Compliance Committee. Mr. Newton previously served as Chief Executive Officer and as a member of the Board of Directors of Apollo Endosurgery, Inc. (Nasdaq: APEN), a medical device company, from July 2014 until March 2021. Earlier in his career, Mr. Newton served as Executive Vice President, Chief Financial Officer and Chief Operating Officer at ArthroCare Corporation (formerly Nasdaq: ARTC), a medical device company, from 2009 to June 2014. Prior to that, Mr. Newton served in a number of executive officer roles, including President and Chief Executive Officer and as a director, at Synenco Energy, Inc., a Canadian oil sands company, from 2004 until 2008. Mr. Newton was a Partner at Deloitte & Touche LLP, a professional services network and accounting organization, from 1994 to 2004. Mr. Newton holds a B.B.A. in accounting from the University of Texas at San Antonio.